Start Date
2022
Description
Lead-212 ( 212Pb) has been identified as a promising candidate for alpha(α)- particle radiotherapies for cancers in preclinical and clinical studies. Using a low molecular weight peptide, the radiotherapy will target with high affinity selective markers highly expressed in cancer cells but found in low concentration in healthy tissue. A radiometal is coupled to a chelator moiety linked to the peptide to deliver the α-particle radiation destroying cancer cells.
To develop a novel Pb specific chelator (PSC) that will provide high affinity to Pb212 and improve the in vitro and in vivo binding pharmacokinetics and stability of progeny of the radiopharmaceutical.
Recommended Citation
Doorn, Eric; Li, Mengshi; Cagle, Brianna; Baumhover, Nicholas; Dai, Zhiming; Liu, Dijie; Vance, Ivy; Johnson, Frances; and Schultz, Michael K., "A novel chelator for Pb-212/Bi-212-based alpha-particle radiotherapy for cancers" (2022). Summer Research. 10.
https://digitalcommons.calvin.edu/summer_research/2022/Posters/10
A novel chelator for Pb-212/Bi-212-based alpha-particle radiotherapy for cancers
Lead-212 ( 212Pb) has been identified as a promising candidate for alpha(α)- particle radiotherapies for cancers in preclinical and clinical studies. Using a low molecular weight peptide, the radiotherapy will target with high affinity selective markers highly expressed in cancer cells but found in low concentration in healthy tissue. A radiometal is coupled to a chelator moiety linked to the peptide to deliver the α-particle radiation destroying cancer cells.
To develop a novel Pb specific chelator (PSC) that will provide high affinity to Pb212 and improve the in vitro and in vivo binding pharmacokinetics and stability of progeny of the radiopharmaceutical.